A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations

Inclusion Criteria: * Histologically or cytologically confirmed advanced/metastatic SCLC or NSCLC * Any of the following tumor tissue based genetic alterations: FGFR1, FGFR2, FGFR3, VEGFA, or PDGFRα amplification; Any FGFR1, FGFR2, or FGFR3 gene fusion; FGFR1, FGFR2, or FGFR3 activating mutation * Availability of tumor tissue sample suitable for the central confirmation of the genetic alteration and exploratory analyses * Eastern Cooperative Oncology Group (ECOG) of 0 or 1 * Measurable disease per RECIST 1.1 * Documented radiographic disease progression following at least one line of therapy in the advanced/metastatic setting Exclusion Criteria: * Tumors that are invading a major vessel; NSCLC tumors abutting to a major vessel * Uncontrolled hypertension, defined as SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg with optimized anti-hypertensive therapy * Uncontrolled hypothyroidism defined as serum thyroid stimulating hormone (TSH) higher than 5 mIU/mL while receiving appropriate thyroid hormone therapy * Symptomatic and/or untreated central nervous system metastases * Presence of another active cancer * Ongoing adverse events from surgery or prior anti-cancer therapies, including radiation, targeted, or cytotoxic therapies * Pregnant or breastfeeding women